President and CEO Elisabeth Lindner comments on the second quarter
Today the President and CEO of Diamyd Medical commented in the company’s semi-annual report on the steady flow of good news that the company has reported during the quarter, concerning five simultaneous trials in a total of ten countries. After the reporting period the company received a capital injection of MSEK 28, through subscriptions for new shares upon exercise of subscription warrant DIAM TO 2B.Diamyd Medical is pursuing its product strategy: treat, prevent and cure - We continue to work diligently on treating, preventing and now also curing type 1 diabetes, three strategies that are